Same data, different analysts: variation in effect sizes due to analytical decisions in ecology and evolutionary biology
Correction: The landscape of BRAF transcript and protein variants in human cancer
C1Q+ TPP1+ macrophages promote colon cancer progression through SETD8-driven p53 methylation
Epidemiological analysis of intra-abdominal infections in Italy from the Italian register of complicated intra-abdominal infections—the IRIS study: a prospective observational nationwide study
Knowledge and management of Münchausen’s Syndrome by proxy: a survey conducted through the compilation of a questionnaire by pediatricians belonging to the Italian Society of Pediatrics
KBG syndrome: report and follow-up on three unrelated patients observed at different ages
Urgent call to the European Commission to simplify and contextualize IVDR Article 5.5 for tailored and precision diagnostics
The European Commission (EC) started targeted evaluations and public consultations regarding the EU IVDR 2017/746 to assess its effectiveness, efficiency, relevance, and EU-added value. The goal is to identify implementation challenges and unintended consequences, experienced by either IVD-manufacturers that put CE-IVDs on the EU market or by medical laboratories that establish and operate in-house-IVDs (IH-IVDs) in their healthcare institution (network). Based on stakeholder feedback the EC aims to be informed about potential regulatory revisions by late 2025. As IH-IVDs, used in different modes, have a vital role in the EU healthcare system, the authors make the statement that Article 5.5 of the IVDR should be systemically amended, removing conditions (a) and (d) through (i) for in-house tests, while retaining conditions (b) and (c). Having the prime objectives of the IVDR in mind, i.e. patient safety and clinical utility, this opinion paper urges the EC to revise IVDR Article 5.5 to prevent disservices to patients and caregivers by taking into account available quality management infrastructure in ISO 15189:2022 accredited medical laboratories and guaranteed professionality of registered laboratory specialists, both already monitored at the level of the EU member states. By abandoning unnecessary, non-valuable requirements from Article 5.5 overregulation is prevented and the sustainability of important specialty and orphan tests, essential for patients with rare diseases, is guaranteed.
Predictive genomic medicine enlarges the spectrum of predisposing mutations for head and neck cancers via a panel of 56 genes selected for human neoplasia in Southern Italy: a pilot study
A note on the coprime power graph of groups
Some years ago, Shitov proved that the chromatic number of the power graph of semi-groups is at most countable, thus answering a question raised by Aalipour et al. about whether this statement holds for groups. Later, Dalal and Kumar proved that the chromatic number of the enhanced power graph of a group is also countable. In the line of these recent works, we first generalize the concept of power graphs to coprime power graph, and then we prove the same type of result for this generalization. Furthermore, we state a conjecture about their common relationship as graphs.